Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination

BNT162b2疫苗接种后,抗刺突蛋白抗体水平低的人群中存在淋巴细胞过早衰老的证据。

阅读:1
作者:Yapei Huang ,Juliana E Shin ,Alexander M Xu ,Changfu Yao ,Sandy Joung ,Min Wu ,Ruan Zhang ,Bongha Shin ,Joslyn Foley ,Simeon B Mahov ,Matthew E Modes ,Joseph E Ebinger ,Matthew Driver ,Jonathan G Braun ,Caroline A Jefferies ,Tanyalak Parimon ,Chelsea Hayes ,Kimia Sobhani ,Akil Merchant ,Sina A Gharib ,Stanley C Jordan ,Susan Cheng ,Helen S Goodridge ,Peter Chen

Abstract

SARS-CoV-2 vaccines have unquestionably blunted the overall impact of the COVID-19 pandemic, but host factors such as age, sex, obesity, and other co-morbidities can affect vaccine efficacy. We identified individuals in a relatively healthy population of healthcare workers (CORALE study cohort) who had unexpectedly low peak anti-spike receptor binding domain (S-RBD) antibody levels after receiving the BNT162b2 vaccine. Compared to matched controls, "low responders" had fewer spike-specific antibody-producing B cells after the second and third/booster doses. Moreover, their spike-specific T cell receptor (TCR) repertoire had less depth and their CD4+ and CD8+T cell responses to spike peptide stimulation were less robust. Single cell transcriptomic evaluation of peripheral blood mononuclear cells revealed activation of aging pathways in low responder B and CD4+T cells that could underlie their attenuated anti-S-RBD antibody production. Premature lymphocyte aging may therefore contribute to a less effective humoral response and could reduce vaccination efficacy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。